Objective-The essential role of platelet activation in hemostasis and thrombotic diseases focuses attention on unveiling the underlying intracellular signals of platelet activation. Disabled-2 (Dab2) has been implicated in platelet aggregation and in the control of clotting responses. However, there is not yet any in vivo study to provide direct evidence for the role of Dab2 in hemostasis and platelet activation. Approach and Results-Megakaryocyte lineage-restricted Dab2 knockout (Dab2 −/− ) mice were generated to delineate in vivo functions of Dab2 in platelets. Dab2 −/− mice appeared normal in size with prolonged bleeding time and impaired thrombus formation. Although normal in platelet production and granule biogenesis, Dab2 −/− platelets elicited a selective defect in platelet aggregation and spreading on fibrinogen in response to low concentrations of thrombin, but not other soluble agonists. Investigation of the role of Dab2 in thrombin signaling revealed that Dab2 has no effect on the expression of thrombin receptors and the outside-in signaling. Dab2 −/− platelets stimulated by low concentrations of thrombin were normal in G αq -mediated calcium mobilization and protein kinase C activation, but were defective in G α12/13 -mediated RhoA-ROCKII activation. The attenuated G α12/13 signaling led to impaired ADP release, Akt-mammalian target of rapamycin and integrin αIIbβ3 activation, fibrinogen binding, and clot retraction. The defective responses of Dab2 −/− platelets to low concentrations of thrombin stimulation may contribute to the impaired hemostasis and thrombosis of Dab2 −/− mice. Conclusions-This study sheds new insight in platelet biology and represents the first report demonstrating that Dab2 is a key regulator of hemostasis and thrombosis by functional interplay with G α12/13 -mediated thrombin signaling. (Arterioscler Thromb Vasc Biol. 2014;34:2404-2412.)
P latelets are anucleated cells derived from megakaryocytes and represent the second most numerous blood cells in the peripheral blood. 1 The essential role of platelet activation in hemostasis, myocardial infarction, and other thrombotic diseases has prompted considerable focus on unveiling the underlying intracellular mechanisms of agonist-induced platelet activation. 2, 3 Thrombin binds to G-protein-linked protease-activated receptors (PARs) and causes G αq -dependent increase in intracellular calcium and protein kinase C (PKC) activity, G α12/13 -dependent Rho activation, G αi -dependent inhibition of adenylyl cyclase, and G βγ -mediated phosphoinositide 3-kinase-Akt activation. 4, 5 Collagen interacts with glycoprotein VI and recruits Syk to the plasma membrane followed by tyrosine phosphorylation of downstream substrates required for platelet activation. 4 The agonist-induced inside-out signaling ultimately activates integrin αIIbβ3 and results in platelet activation, secretion, and aggregation.
Cytoskeleton remodeling occurs at different stages of platelet activation. 6 After adhesion to surfaces coated with fibrinogen or collagen, platelets form broad, actin filament-containing lamellae and spread over an area of several micrometers squared. During platelet activation, the cytoplasmic domain of integrin αIIbβ3 associates with actin filaments and intracellular signaling molecules including talin, vinculin, zyxin, paxillin, filamin, and α-actinin. [7] [8] [9] [10] Integrin αIIbβ3-mediated clot retraction then occurs through the action of nonmuscle myosin IIA and IIB that are attached to actin and contract the actin filaments. 11 Despite extensive studies, the underlying mechanisms of agonist-induced inside-out signaling and cytoskeleton reorganization still wait to be fully elucidated.
Disabled-2 (Dab2) is an adaptor protein with at least 2 isoforms p82 (p96) and p59 (p67) being generated through alternative splicing. 12 p59-Dab2 lacks the ninth coding exon corresponding to the amino acids 230 to 445 of p82-Dab2, resulting in the deletion of several binding sites for endocytic proteins. 12 By interactions with other cellular factors through the N-terminal phosphotyrosine binding domain, the aspartic acid-proline-phenylalanine motif, and the C-terminal proline-rich region, 7, [13] [14] [15] [16] Dab2 elicits functions in cytoskeleton reorganization, endocytosis, differentiation, and cell signaling. [17] [18] [19] [20] Dab2 is known to regulate the signaling pathways of Ras-mitogen-activated protein kinase, Wnt, transforming growth factor-β, and RhoA-ROCK [14] [15] [16] 21 and modulate cytoskeleton reorganization by binding to actin, myosin VI, nonmuscle myosin heavy chain IIA, and dynein. 17, 19, 22 Dab2 is abundantly expressed in human platelets and is distributed mainly in the cytoplasm and α-granules. 23 It is upregulated during megakaryocytic differentiation of human CD34 + hematopoietic pluripotent stem cells, murine embryonic stem cells, and human leukemic K562 cells. 13, 20, 24 In vitro studies have identified Dab2 as a regulator of platelet integrin activation, cell adhesion, and fibrinogen uptake. 13, 25 Dab2 is released and binds to either integrin αIIb or phospholipid sulfatide in response to platelet activation, playing a role in platelet-fibrinogen and platelet-leukocyte adhesion and aggregation. 23, 26 The balance between sulfatide-and integrin receptor-bound states is involved in the control of the extent of clotting response. 26, 27 Nevertheless, there is not yet any in vivo study to provide direct evidence for the role of Dab2 in thrombosis and hemostasis.
In this study, megakaryocyte/platelet lineage-restricted Dab2 knockout (Dab2 −/− ) mice were generated by using the PF4-Cre transgenic system. 28 We report here that PF4-Credriven Dab2 −/− mice display a prolonged bleeding time and impaired thrombus formation. Dab2-deficient platelets are impaired in platelet aggregation, spreading on fibrinogen and clot retraction in response to low concentrations of thrombin. The functional defect of Dab2-deficient platelets is correlated with the lack of responsiveness to thrombin-induced RhoA-ROCKII and Akt-mammalian target of rapamycin (mTOR) activation, ADP release, and integrin αIIbβ3 activation. This study defines Dab2 as a key regulator of thrombosis and hemostasis by playing a selective role in thrombin-stimulated inside-out signaling in platelets.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Generation of Megakaryocyte Lineage-Restricted Dab2 −/− Mice
To determine the in vivo roles of Dab2 in platelet function, megakaryocyte lineage-restricted Dab2 −/− mice were generated by cross-breeding Dab2 fl/fl mice with PF4-Cre mice to ablate exon 2 of DAB2 gene. Genotyping of Dab2 −/− tail genomic DNA by polymerase chain reaction revealed the polymerase chain reaction products of 530 and 450 bp corresponding to the alleles of DAB2 and PF4-Cre, respectively ( Figure 1A ). Sequencing of the reverse transcriptase-polymerase chain reaction product from a single Dab2 −/− megakaryocyte revealed the presence of a truncated DAB2 transcript, indicating successful ablation of DAB2 gene by Cre-recombinase ( Figure 1B) .
After BSA density gradient and cell sorting to enrich CD41 + /Gr1 − megakaryocytes for >85% purity, both p82 and p59 Dab2 proteins were detectable in Dab2 fl/fl but not in Dab2 −/− megakaryocytes ( Figure 1C ). Dab2 expression in the nonmegakaryocytic small cell population obtained from the upper layer of the BSA density gradient was not affected. Immunofluorescence staining using anti-Dab2 antibody further confirmed a lack of Dab2 expression in Dab2 −/− megakaryocytes ( Figure 1D ).
Western blot analysis was then performed to characterize Dab2 expression in Dab2 −/− platelets. p59 was the sole Dab2 isoform in Dab2 fl/fl platelets, and its expression was abrogated in Dab2 −/− platelets ( Figure 1E ). These data confirm the generation of megakaryocyte/platelet-restricted Dab2-deficient mice.
Dab2 −/− Mice Display Impaired Hemostasis and Thrombosis With No Defect in Platelet Production and Granule Biogenesis
Dab2 −/− mice were viable with no evidence of spontaneous bleeding or hemorrhage and no apparent differences in size and weight when compared with Dab2 fl/fl mice. A bleeding time assay was performed to explore the primary hemostasis function of Dab2 after injury. Dab2 −/− mice had an average bleeding time of 308.4±56.4 seconds that was significantly increased when compared with 171.5±36.9 seconds for Dab2 fl/fl mice (P=0.039 by log-rank test; Figure 2A ). We noted that 29.2% of Dab2 −/− mice had excessive bleeding (lasting >10 minutes) when compared with 11.8% of Dab2 fl/fl mice. In contrast, the rebleeding rate is similar for Dab2 −/− and Dab2 fl/fl mice (58.8% versus 54.8%; Figure 2B ).
Thrombus formation in Dab2 −/− mice was evaluated using a FeCl 3 -induced mesenteric venules/arterioles thrombosis model. In control mice, the thrombus was compact and occupied the entire injured surface, as judged by the uniform intensity of fluorescence ( Figure 2C ). In contrast, the injured surface was not uniformly covered by thrombus in Dab2 −/− mice, as observed by the lack of homogeneity of the fluorescence signal ( Figure 2C ; Movie I in the online-only Data Supplement). The occlusion time was much slower in Dab2 −/− compared with control venules (36.6±1.7 and 14.8±2.4 minutes, respectively; P<0.001) and arterioles (38.3±1.8 and 12.2±1.2 minutes, respectively; P<0.001; Figure 2D ). These data indicate that Dab2 −/− mice elicit impaired primary hemostasis and thrombus formation.
To determine whether the changes in hemostasis and thrombus formation of Dab2 −/− mice are because of the defect in hematopoiesis and platelet production, hematological profiles of Dab2 −/− mice were determined. Blood counts were comparable between Dab2 −/− and Dab2 fl/fl mice ( Figure 2E 
Dab2 −/− Platelets Are Selectively Defective in Thrombin-Induced Aggregation, Platelet Spreading on Fibrinogen, and Clot Retraction
Agonist-induced platelet aggregation assays were performed to elucidate the effects of Dab2 deficiency on platelet function. Dab2 −/− platelets responded normally to collagen, U46619, ADP, and high concentrations of thrombin and PAR4 peptide. However, the responsiveness of Dab2 −/− platelets to low concentrations of thrombin (0.05 U/mL) and PAR4 peptide (0.15 mmol/L) was significantly decreased ( Figure 3A) . At the end of the assays, the percentage of light transmission for thrombin (0.05 U/mL) treatment was 49.4±7.4% and 13.3±8.5% for Dab2 fl/fl and Dab2 −/− platelets, respectively (P<0.01; Figure 3B ). The percentage of light transmission for PAR4 peptide (0.15 mmol/L) treatment was 51.6±3.5% and 29.5±7.7% for Dab2 fl/fl and Dab2 −/− platelets, respectively (P<0.05; Figure 3B ). These data indicate that Dab2-deficient platelets are defective in response to low concentrations of thrombin and PAR4 peptide. Platelet-fibrinogen interaction is important for the primary hemostatic plug and thrombus formation. The adhesion and spreading of Dab2 −/− platelets on immobilized fibrinogen were analyzed ( Figure 4A and 4B). The number of Dab2 −/− platelet adhesions on fibrinogen was similar to the Dab2 fl/fl platelets ( Figure 4B , left panel). At the resting stage, Dab2 fl/fl and Dab2 −/− platelets did not spread well on fibrinogen, consistent with a previous report. 29 On thrombin stimulation, a large portion of Dab2 −/− platelets had rounded morphology with limited lamellipodia formation. The number of Dab2 −/− platelets spread on fibrinogen (39.9±6.9) was decreased when compared with the Dab2 fl/fl platelets (88.9±15.3; P<0.05; Figure 4B , middle panel). The increase in surface area of spread of Dab2 −/− platelets was 56.7±13.7% of Dab2 fl/fl platelets (P<0.05; Figure 4B , right Figure 4A and 4B), indicating that Dab2 acts on the thrombin-but not ADPstimulated inside-out signaling. Dab2 −/− and Dab2 fl/fl platelets also spread equally on fibrinogen when stimulated by MnCl 2 (an exogenous activator of the integrin; Figure 4A and 4B), revealing that Dab2 deficiency does not affect the outside-in signaling of integrin αIIbβ3.
Clot retraction is mediated by binding of fibrinogen to the activated integrin αIIbβ3 leading to contraction of platelets. Clot retraction assay revealed that Dab2 fl/fl platelets started to retract at 30 minutes and were completely retracted by 2 hours, whereas Dab2 −/− platelets showed only partial retraction by 2 hours ( Figure 4C ). After quantifying the clot area, the percentage of clot retraction was 73.5±6.0% for Dab2 fl/fl platelets, which was significantly different than 49.2±6.3% for Dab2 −/− platelets (P<0.05; Figure 4C ). These data indicate that Dab2 deficiency results in a defect in thrombin signaling leading to impaired platelet spreading on fibrinogen and clot retraction.
Dab2 Deficiency Causes a Decrease in Platelet Fibrinogen Storage and Thrombin-Stimulated ADP Release and Integrin αIIbβ3 Activation
Dab2 has been shown to play a role in fibrinogen internalization in human K562 cells. 25 The fibrinogen content in Dab2 −/− platelets was analyzed to investigate whether Dab2 deficiency has any effect on fibrinogen storage in platelets. Western blot analysis revealed that Dab2 fl/fl and Dab2 −/− mice had similar amounts of plasma fibrinogen ( Figure 5A ). However, the fibrinogen content in Dab2 −/− platelets was ≈63% of the control (P<0.05; Figure 5B ), implicating a selective defect of Dab2 −/− platelets in fibrinogen storage. Adding exogenous fibrinogen in the reaction mixtures was not able to restore thrombin-induced aggregation response of Dab2 −/− platelets ( Figure 5C ). These data imply that the decrease in fibrinogen storage does not account for the attenuated response of Dab2 −/− platelets to low concentrations of thrombin.
The effects of Dab2 deficiency on thrombin signaling was delineated further in the following experiments. Surface CD41 expression and thrombin-stimulated α-granule release as indicated by the surface expression of CD62P were normal in Dab2 −/− platelets ( Figure 5D and 5E). In contrast, low concentrations of thrombin induced less release of ADP, less integrin αIIbβ3 activation, and less fibrinogen binding from 
Dab2 Regulates Thrombin-Stimulated Inside-Out Signaling
To elucidate the molecular insight for Dab2 function in thrombin signaling, we first analyzed whether the expression of thrombin receptors was altered in Dab2 −/− platelets. Flow cytometry and Western blot analyses revealed that the expression levels of thrombin receptors GPIbα, PAR3, and PAR4 were comparable between Dab2 fl/fl and Dab2 −/− platelets ( Figure 6A ), ruling out aberrant thrombin receptor expression as the cause of impaired thrombin signaling in Dab2 −/− platelets.
The inside-out signaling of thrombin is mainly transmitted through the G-protein-dependent pathways that cause an increase in intracellular calcium concentration and signaling proteins phosphorylation. 5 Analyses of the molecular events downstream of thrombin receptors revealed that the intracellular calcium concentration and the phosphorylation of PKC-pan, PKCδ-T505, and PDK1-Ser241 stimulated by low concentrations of thrombin were similar between Dab2 fl/fl and Dab2 −/− platelets ( Figure 6B and 6C) , whereas G α12/13dependent Rho activation as represented by the phosphorylation of ROCKII (a downstream effector of RhoA) at Ser1366 30 in Dab2 −/− platelets was 62.4±10.5% of the control (P<0.05; Figure 6C ). The phosphorylation of Akt-Ser473 and mTOR-Ser2448 in Dab2 −/− platelets were also significantly attenuated to 35.3±8.9% and 48.8±10.1% of the control, respectively (P<0.01 and <0.05; Figure 6C ). These defects were not apparent if Dab2 −/− platelets were stimulated with high concentrations of thrombin (0.5 or 1 U/mL) or other soluble agonists such as collagen, U46619, and ADP ( Figure 6C ; Figure I in the online-only Data Supplement). These data indicate that Dab2 mediates signaling by low doses of thrombin and acts upstream of RhoA-ROCK and Akt-mTOR. Platelet aggregation and Akt-Ser473 phosphorylation stimulated by low thrombin concentrations were inhibited by apyrase in Dab2 fl/fl platelets and were restored by ADP in the Dab2 −/− platelets in a dose-dependent manner ( Figure 6D) . These data indicate that impaired ADP release contributes to the defective platelet aggregation and Akt phosphorylation of Dab2 −/− platelets.
Discussion
Our results define a key in vivo function for Dab2 in regulating hemostasis, thrombosis, and platelet signaling in mice. Absence of Dab2 does not influence the process of platelet biogenesis, but selectively inhibits the phosphorylation of ROCKII-Ser1366, Akt-Ser473, and mTOR-Ser2448 under conditions of low-dose thrombin stimulation. The impairment of the signaling response in Dab2 −/− platelets causes functional changes in ADP release, integrin αIIbβ3 activation, fibrinogen binding, platelet aggregation, spreading on fibrinogen, and clot retraction. In accord with the aforementioned functional defects of Dab2 −/− platelets, Dab2 −/− mice display a prolonged bleeding time and impaired thrombus formation. This study presents novel evidence demonstrating that Dab2 plays an important role in hemostasis, thrombosis, and platelet signaling in vivo.
Various signaling pathways are activated when platelets are stimulated with different types of agonists. Collagen induces clustering of glycoprotein VI and causes an increase in glycoprotein VI-associated Src family kinase activity, leading to a rise in intracellular calcium and an increase in PKC activity. 31, 32 The receptors of thrombin and thromboxane A2 couple to both G αq and G α12/13 pathways, whereas ADP binds to P2Y 1 and P2Y 12 receptors that couple to G αq and G αi , respectively, for signal propagation. 33 GPIbα is apparently another type of thrombin receptor. 34, 35 Because the expression levels of PAR3, PAR4, and GPIbα are similar between Dab2 −/− and wild-type platelets, the selective defects of Dab2 −/− platelets in response to low thrombin concentrations are not attributed to the altered expression of thrombin receptors. Instead, Dab2 −/− platelets are impaired in G α12/13 -mediated RhoA activation as shown by the decreased ROCKII-Ser1366 phosphorylation. This is consistent with the previous study showing that Dab2 modulates RhoA activity and inhibits nerve growth factor-induced neurite outgrowth. 21 Dab2 −/− and RhoA −/− mice are abnormal in hemostasis and thrombus formation, whereas the corresponding platelets are defective in integrin activation, clot retraction, and dense granule/ADP secretion in response to low concentrations of thrombin. In contrast, Dab2 −/− and RhoA −/− platelets response normally to ADP and collagen-stimulated platelet aggregation. 36 These results imply that Dab2 and RhoA-ROCKII are in the same signaling axis.
Discrepancies between Dab2 −/− and RhoA −/− platelets are also noted. For example, RhoA −/− but not Dab2 −/− platelets are defective in P-selectin exposure in response to thrombin. 36 This is explainable by the broad spectrum of RhoA function, which plays a central role in G α12/13 signaling and also contributes to G αq -mediated platelet activation. 37 Several indirect studies indicate that G αq may directly regulate RhoA activity by activating the Rho-guanine nucleotide exchange factors. 38 In contrast, Dab2 seems to restrict its function in G α12/13 -associated RhoA-ROCK activation with no evidence for cross-talk of Dab2 to G αq ; Dab2 −/− platelets are normal in G αq -mediated calcium mobilization and PKC phosphorylation in response to thrombin. This study reveals for the first time the functional interplay of Dab2 with G α12/13 -mediated RhoA-ROCK activation in murine platelets.
Because Src family kinase and G αi /G βγ /G αq are the major signaling pathways mediating platelet activation by collagen and ADP, respectively, the restricted function of Dab2 in the G α12/13 pathway also explains the normal aggregation patterns of Dab2 −/− platelets in response to collagen and ADP. Despite G α12/13 coupling to the thromboxane A2 receptors, Dab2 −/− platelets are not defective in platelet aggregation stimulated by the thromboxane A2 mimetic U46619. Similar to our findings, Lyn-deficient platelets are defective in aggregation stimulated by low concentrations of thrombin and PAR4, but produce normal aggregation by U46619 and ADP. 39 These studies highlight the presence of agonist-specific signaling downstream of G α12/13 pathway.
Another important finding in this study is that Dab2 −/− platelets are normal in PDK1-Ser241 phosphorylation, but are impaired in ADP release, platelet aggregation, and the phosphorylations of Akt-Ser473 and mTOR-Ser2448. The defective platelet aggregation and Akt-Ser473 phosphorylation were rescued and restored by supplementation of ADP to the reaction. These data indicate that Akt-Ser473 phosphorylation is independent of PDK1 signaling, consistent with the notion that the mTOR complex 2 complex is responsible for the phosphorylation of Akt-Ser473. 40 Based on the findings in this study, a possible working model for the mechanisms of Dab2 action in thrombin-stimulated inside-out signaling is proposed. In response to low concentrations of thrombin, Dab2 regulates G α12/13 -mediated RhoA-ROCK activation and potentiates ADP release. The released ADP binds to its receptor P2Y 12 and activates G αi /G βγ signaling leading to Akt-mTOR phosphorylation/activation, which potentiates integrin activation and platelet aggregation. This mode of Dab2 action is consistent with previous studies showing that G α12/13 -mediated RhoA-ROCK activation regulates cytoskeleton reorganization, which is critical for degranulation, 41 whereas ADP release is essential to stabilize platelet aggregates stimulated by concentrations of thrombin <0.25 to 1 U/mL but is not required at high thrombin concentrations. 42 Despite the fact that Dab2 elicits a restrictive function in response to low thrombin concentrations, but not other soluble agonists, Dab2 deficiency has profound effects on hemostasis and thrombosis in vivo, as evidenced by Dab2 −/− mice having a prolonged bleeding time and impaired thrombus formation. Consistent with our findings, even a partial decrease in thrombininduced platelet aggregation observed in PAR3-deficient mice impairs hemostasis and protects against thrombosis. 43 Similarly, blocking thrombin receptor PAR4 on platelets extends bleeding time and protects against systemic platelet activation. 44 This and other studies support the perception that thrombin signaling plays a pivotal role in hemostasis and thrombosis.
The defect in fibrinogen storage does not particularly contribute to the defective response of Dab2 −/− platelets to low concentrations of thrombin. Nevertheless, this and other studies indicate that Dab2 positively regulates fibrinogen uptake. Fibrinogen uptake in K562 cells is a Dab2-dependent process. 25 Expression of shDAB2 in rat megakaryocytes results in a moderate decrease in fibrinogen uptake ( Figure II in the online-only Data Supplement). At the molecular level, Dab2 is known to bind the β3-NITY motif of the fibrinogen receptor integrin αIIbβ3 through the PTB domain 7, 13 and act as an NPXY sequence-specific clathrin adaptor protein in receptor endocytosis. 17, 45, 46 With two thirds of the normal fibrinogen content still present in Dab2 −/− platelets, a Dab2-dependent and a Dab2-independent mechanism for fibrinogen internalization could occur in platelets.
Not all the observations obtained from Dab2 −/− mice are consistent with our previous analyses using human cell lines and platelets. In K562 cells, Dab2 knockdown augments rather than weakens integrin αIIbβ3 activation and increases cell adhesion to fibrinogen. 13 In human platelets, Dab2 negatively regulates platelet-fibrinogen interaction and platelet aggregation. 13, 23, 26, 47 Dab2 is required for murine platelet aggregation in response to low concentrations of thrombin. Several issues could be argued for the discrepancy among these studies. First, different Dab2 isoforms are present in human and murine platelets. Human platelets mainly expressed p82, whereas p59 is the sole Dab2 isoform in murine platelets ( Figure III in the online-only Data Supplement). Distinct functions of p82 and p59 have been reported. p82 has been shown to function in receptor-mediated endocytosis, whereas p59 can act as a transcriptional regulator during the differentiation of F9 cells. [48] [49] [50] [51] In Dab2 −/− mice, expression of p59 only partially compensates for the absence of Dab2. 12 Hence, species-specific expression of Dab2 isoforms may explain the distinct features of Dab2 in human and mouse megakaryocytes and platelets.
The discrepancy between this and previous studies could simply be because of the use of different experimental models. In the human platelet studies, the experiments were mainly performed in vitro using recombinant Dab2 protein as a tool to analyze Dab2 function and its effects on platelet response. 23, 26 No in vivo study was performed using Dab2 mutants or Dab2deficient human platelets. In contrast, Dab2-deficient mouse platelets were used in the present study to analyze in vivo Dab2 function. Future study using an animal model system with expression of human platelet Dab2 protein may provide additional insight for the differential Dab2 function in human and mouse platelets.
In conclusion, the findings that Dab2 expression is required for (1) hemostasis and thrombosis, (2) fibrinogen storage, (3) thrombin-stimulated inside-out signaling, and (4) optimal ADP release, integrin αIIbβ3 activation, and fibrinogen binding leading to platelet aggregation, spreading on fibrinogen, and clot retraction stimulated by low thrombin concentrations are the first demonstration that Dab2 plays an important role in efficient hemostasis and platelet activation by thrombin in vivo.
